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	ABSTRACT 
 
Background/Purpose:  One proposed mechanism of antiphospholipid antibody 
(aPL)-mediated thrombosis is disruption of the Annexin A5 (AnxA5) anticoagulant 
shield, allowing initiation of coagulation reactions on phospholipid surfaces.  The 
AnxA5 resistance assay (AnxA5-RA) measures resistance to AnxA5 anticoagulant 
activity in the plasmas of aPL-positive patients. Based on in vitro studies, 
hydroxychloroquine (HCQ) interferes with aPL binding to cell surfaces and helps 
repair disrupted AnxA5 shields; however, no in vivo human studies exist. Other non-
criteria aPL tests, including anti-domain-I 2-glycoprotein-I IgG (aDI-2GPI) and 
activated protein C (APC) resistance may be associated with thrombosis in patients 
with antiphospholipid syndrome (APS). The purpose of this prospective study is to 
determine the effect of HCQ on the AnxA5-RA, as well as criteria and other non-
criteria aPL tests, in persons with aPL. 
 
Methods:  We recruited persons with aPL (lupus anticoagulant [LAC], anticardiolipin 
antibody [aCL] ≥ 40 GPL/MPL, and/or anti-2-glycoprotein-I [a2GPI] antibody ≥ 40 
SGU/SMU at two time points at least 12 weeks apart) starting HCQ to give blood at 
baseline, 6 weeks, and 12 weeks (primary outcome measure: AnxA5-RA; secondary 
outcome measures: LAC, aCL, a2GPI, aDI-2GPI, APC resistance, and D-dimer). As 
a control group, we also recruited aPL (LAC, aCL, and a2GPI)-negative systemic 
lupus erythematosus (SLE) patients starting HCQ . We compared the baseline 
	characteristics of patients with aPL to aPL-negative SLE patients (Mann-Whitney test) 
as well as a change in results from baseline to week 12 (Wilcoxon signed-rank test).  
 
Results: We compared baseline data from 21 aPL-positive patients (mean age 44.7  
11.0 years [range 27-61], 15 [71%] female, 17 [81%] Caucasian; 13 had APS and 8 
had asymptomatic aPL) to 12 aPL-negative SLE patients (mean age 45.4  15.0 years 
[range 22-64], 12 [100%] female, 7 [58%] Caucasian). Mean baseline values for 
AnxA5-RA were lower (more abnormal) for aPL-positive subjects compared to aPL-
negative subjects (134.1  15.6 vs. 168.3  21.9; p<0.0001); no patients in the aPL-
negative group exhibited resistance to AnxA5 anticoagulant activity. Mean baseline 
values of aDI-2GPI were higher for aPL-positive subjects as compared to aPL-
negative subjects (4.40  4.38 vs. 0.76  0.44; p=0.0002); no patients in the aPL-
negative group had aDI-2GPI. There was no significant change between mean 
baseline and week 12 values for LAC, aCL, a2GPI, AnxA5-RA, aDI-2GPI, APC 
resistance, or D-dimer in aPL-positive subjects receiving HCQ (Table). 
 
 
	Table: Comparison of Baseline and Week 12 Values for Non-criteria aPL Tests in 
aPL-positive subjects (n=17) 
 Baseline  12 weeks p Reference Range 
AnxA5-RA (%) 
(Mean + SD) 
136.6.1  16.0 143.96 ± 25.6 0.2435 
Negative 153 
Borderline 140-152.9 
Positive <140 
aDI-β2GPI (mg/L) 
(Mean + SD) 
4.45  4.80 4.01  4.40 0.9265 
Negative 1.66 
Borderline 1.66-2.29 
Positive >2.29 
APC resistance 
ratio* 
2.69  0.63 2.52  0.92 0.7002 Abnormal <2.0 
D-dimer (µg/mL) 
(Mean + SD) 
1.73  0.72 1.58  0.72 0.1743 Normal 
0.8-2.3 
AnxA5-RA: Annexin-A5 resistance assay; aDI-2GPI: anti-domain-I 2-glycoprotein-I antibody; 
APC: activated protein C; SD: standard deviation 
* n = 14 
 
 
Conclusion: Patients with aPL have positive AnxA5-RA and aDI-2GPI; our findings 
support the use of these non-criteria tests to detect aPL. HCQ use was not associated 
with a change in AnxA5 anticoagulant activity or other criteria or non-criteria aPL 
tests; duration of HCQ treatment, HCQ dosing, sample size, and lack of efficacy in 
vivo are possible explanations for these findings. Our findings suggest that HCQ may 
not act through an AnxA5 resistance mechanism.  
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Introduction 
 
Antiphospholipid syndrome (APS) is an autoimmune disorder of thrombosis and/or 
pregnancy complications combined with antiphospholipid antibodies (aPL), classified 
by the Sapporo criteria,1 which require laboratory tests to be positive at two points in 
time, at least 12 weeks apart, and must include at least one of the following tests: 
lupus anticoagulant (LAC), anticardiolipin (aCL) enzyme-linked immunosorbent 
assay (ELISA), and/or anti-2-glycoprotein-I (a2GPI) ELISA.  
 
A proposed mechanism for thrombosis in APS is aPL-mediated disruption of the 
annexin A5 (AnxA5) layer that shields phospholipid bilayers from aPL binding.  
AnxA5 is a potent anticoagulant protein on the surfaces of platelets and endothelial 
cells that protects against thrombosis in vitro.2  Plasma containing antiphospholipid 
antibodies may disrupt the anticoagulant shield produced by AnxA5; clotting may 
ensue.  The AnxA5 resistance assay (AnxA5-RA) is a functional coagulation assay 
that defines resistance to AnxA5 anticoagulant activity; it measures the degree to 
which antiphospholipid antibodies in the patient plasma interfere with the protective 
AnxA5 layer.3   
 
Antiphospholipid antibodies against the phospholipid binding protein, 2GPI, are 
closely associated with thrombosis in APS. 2GPI comprises 5 domains (DI-V); 
a2GPI targeted against the N-terminal domain of 2GPI (known as domain I), are 
anti-domain-I 2GPI antibodies (aDI-2GPI) and are strongly associated with both 
obstetric and thrombotic events. In addition, aDI-2GPI activity correlates with 
AnxA5 resistance in LAC-positive samples, suggesting a link between aDI- 2GPI and 
LAC.4   
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Acquired resistance to activated protein C (APC) occurs in APS patients and is a 
proposed mechanism for thrombosis5; APC resistance may function as a non-criterion 
aPL test in patients who do not possess the Factor V Leiden mutation. Elevated levels 
of D-dimer, a nonspecific clinical marker of thrombosis, correlate with arterial and 
venous thrombosis.6,7 . 
 
Hydroxychloroquine (HCQ), an antimalarial drug widely used in the treatment of 
autoimmune disorders like systemic lupus erythematosus (SLE), has anticoagulant 
properties. In aPL-injected mice, HCQ decreases the thrombus size and the time of 
thrombus formation in a dose-dependent manner.8 Rand et al. demonstrated that HCQ 
reverses the binding of aPL-ß2GPI complexes to phospholipid bilayers and protects the 
AnxA5 anticoagulant shield from disruption by aPL in vitro.9,10 Studies of large lupus 
cohorts demonstrate that HCQ decreases risk of thrombosis.11-14  Of note, despite the 
lack of high quality clinical evidence, clinicians prescribe HCQ “off-label” for the 
management of persons with aPL without other systemic autoimmune diseases, 
especially for those with non-criteria manifestations of aPL. 
 
Here we evaluate the effect of short-term HCQ use on both criteria (LAC, aCL, and 
a2GPI) and non-criteria (AnxA5-RA, aDI-2GPI, and APC resistance) aPL tests in 
persistently aPL-positive individuals.  
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Materials and Methods 
 
Study Design 
We conducted a single-center, observational, hypothesis-generating pilot study in 
which patients with aPL subjects starting treatment with HCQ as part of standard of 
care were followed over a 12-week period.  The primary objective was to explore the 
effect of HCQ on AnxA5 resistance.  The secondary objectives were to explore the 
effects of HCQ on LAC, aCL, a2GPI, aDI-2GPI APC resistance, and D-dimer.   
 
Study Population 
The target population included aPL-positive individuals (both those with APS and 
those with aPL but without vascular thrombosis or pregnancy morbidity), with or 
without SLE.  We recruited subjects from private rheumatologists’ offices and the 
Lupus Clinic at the Mary Kirkland Center for Lupus Care at Hospital for Special 
Surgery (HSS).   
 
Inclusion criteria 
Eligible persons were age 18 to 65 who had received a prescription for HCQ and who 
fulfilled at least one of the following criteria: 1) a positive LAC test, as defined by the 
International Society on Thrombosis and Haemostasis,8 on 2 occasions, at least 12 
weeks apart, 2) a positive aCL IgG and/or IgM isotype (at least 40 units) on 2 
occasions, at least 12 weeks apart, and/or 3) a positive a2GPI IgG and/or IgM isotype 
(at least 40 units) on 2 occasions, at least 12 weeks apart.  
 
We recruited individuals with SLE (fulfilling at least four of the criteria for the 
American College of Rheumatology for the classification of SLE9) into two aPL-
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negative control groups – those starting HCQ and those not starting HCQ.  Negative 
aPL was defined by all three of the following within one year prior to enrollment: 1) a 
negative LAC test, 2) aCL IgG/IgM/IgA isotype < 20 units, and 3) a2GPI 
IgG/IgM/IgA isotype < 20 units.   
 
Exclusion criteria  
Patients were ineligible if they fulfilled any of the following criteria : HCQ or 
chloroquine use within the past 6 months; prednisone or other steroid equivalent at a 
dose of 0.5 mg/kg at the time of enrollment; current heparin use; the use of any 
disease-modifying anti-rheumatic drug, cytotoxic, or biologic medication in the past 3 
months; pregnancy; acute thrombotic event in the past 2 weeks; or active malignancy. 
 
Study interventions 
The Institutional Review Board at HSS approved the study design, which complied 
with the Health Insurance Portability and Accountability Act.  All subjects gave 
written informed consent.  The study is listed on ClinicalTrials.gov (NCT01475149).   
 
Baseline data collection included demographic information, SLE- and aPL-specific 
histories, historical aPL profiles, medications, and Systemic Lupus Erythematosus 
Disease Activity Index (SLEDAI)10 and Systemic Lupus International Collaborating 
Clinics/American College of Rheumatology damage index (SDI)11 measurements.  We 
conducted follow-up visits at weeks 6 and 12 and interviewed study participants by 
telephone using a standardized questionnaire at weeks 1, 3, and 9 to assess for 
compliance with HCQ and side effects.   
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We collected serum and plasma samples at baseline, 6, and 12 week visits for freezing 
and storing for later analysis by the clinical laboratory at Montefiore Medical Center. 
We tested samples for LAC; aCL IgG, IgM and IgA; aβ2GPI IgG, IgM and IgA; aDI-
β2GPI antibodies; APC resistance; and D-dimer assay.  
 
Lupus anticoagulant was measured using the STA®-Staclot® DRVV Screen and 
STA®-Staclot® DRVV Confirm lupus anticoagulant kits (Diagnostica Stago, 
Parsippany, NJ), according to the manufacturer’s instructions. Anticardiolipin IgG, 
IgM, and IgA and a2GPI IgG, IgM, and IgA were measured using Anti-Cardiolipin 
EIA and Anti-2 Glycoprotein I EIA test kits (Bio-Rad Laboratories, Hercules, CA), 
according to the manufacturer’s instructions. Annexin A5 resistance and aDI-2GPI 
IgG were measured as previously described.12 Activated protein C resistance was 
measured using a Chromogenix APC Resistance-V kit (DiaPharma Group, Inc., West 
Chester, OH) in accordance with the manufacturer’s instructions. D-dimers were 
measured using Innovance D-dimer kits (Dade Behring, Marburg, Germany), 
according to the manufacturer’s instructions. 
 
Statistical analysis 
To compare baseline medians between the different groups, we used the Mann-
Whitney test.  To compare median baseline and week 12 values within groups, we 
used the Wilcoxon signed-rank test (paired differences). 
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Results 
 
We screened one hundred thirty-three patients, of whom we recruited thirty-three 
between November 2010 and January 2013.  Patients with aPL starting HCQ 
constituted two groups, those with APS and those with asymptomatic aPL. We 
recruited control subjects with SLE only (aPL-negative) into one of two groups, those 
starting HCQ and those not starting HCQ.  
 
Table 1 shows the baseline demographic and clinical characteristics of participants in 
the study. The majority of the population was female (82%) and Caucasian (73%). All 
APS patients had thrombotic events in the past; none had a history of obstetric events. 
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Table 1. Baseline demographic and clinical characteristics of study participants  
 aPL positive aPL negative 
Characteristic APS (n=13) 
Asymptomatic 
aPL (n=8) 
SLE only starting 
HCQ 
(n=8) 
SLE only not 
starting HCQ 
(n=4) 
Age, mean ±  
SD years 44.2 ±10.9 45.4 ±11.7 39.7 ±15.1 56.8 ±6.3 
Female 8 (61.5) 7 (87.5) 8 (100) 4 (100) 
Race  
Asian 1 (7.7) 1 (12.5) 0 0 
African 
American 1 (7.7) 0 2 (25) 1 (25) 
Caucasian 10 (76.9) 7 (87.5) 5 (62.5) 2 (50) 
Other 0 0 1 (12.5) 1 (25) 
Pacific Islander 1 (7.7) 0 0 0 
Hispanic 3 (23.1) 1 (12.5) 3 (37.5) 0 
aPL status  
+LAC 8 (62) 4 (50) 0 0 
+aCL 8 (62) 4 (50) 0 0 
+a2GPI 11 (85) 8 (100) 0 0 
Mean SLEDAI at 
enrollment 1.15 1.375 2.25 5 
Mean SLICC at 
enrollment 1 0.625 1.125 4.75 
SLE  2 (15) 2 (25) 8 (100) 4 (100) 
Medications  
Aspirin 6 (46.2) 5 (62.5) 0 1 (25) 
Warfarin 9 (69.2) 0 0 0 
Fondaparinux 1 (7.7) 0 0 0 
Statin 1 (7.7) 3 (37.5) 0 0 
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Of the 33 subjects recruited, 6 discontinued the study prior to the 6-week study visit. 
Reasons for discontinuation included: gastrointestinal upset after starting HCQ (2), 
subject decided not to start HCQ (1), SLE flare requiring initiation of 
immunosuppressive medication (2), and lost to follow up (1). An additional 2 subjects 
discontinued the study after the 6-week study visit but before the 12-week visit due to 
new pregnancy (1) and lost to follow up (1). There were no thrombotic events during 
the study period. 
 
Baseline data 
We analyzed baseline data for all 33 subjects. Baseline values for the AnxA5-RA, 
aDI- β2GPI, and APC resistance differed significantly between aPL-positive and aPL-
negative subjects, while baseline D-dimer values did not (Table 2).  
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Table 2. Baseline Values of Non-Criteria aPL Tests for aPL-positive and aPL-negative 
Subjects (n=33) 
 aPL (+), n: 21 aPL (-) SLE, n: 12 p Reference Range 
AnxA5-RA (%) 
(Mean + SD) 
134.1  15.6 168.3 ± 21.9 <0.0001 
Negative 153 
Borderline 140-152.9 
Positive <140 
aDI-β2GPI (mg/L) 
(Mean + SD) 
4.40  4.38 0.76  0.44 0.0002 
Negative 1.66 
Borderline 1.66-2.29 
Positive >2.29 
APC resistance 
ratio 
2.7  0.6* 3.2  0.6 0.0085 Abnormal <2.0 
D-dimer (µg/mL) 
(Mean + SD) 
1.77  0.67 1.60  1.35 0.1444 Normal 
0.8-2.3 
AnxA5-RA: Annexin-A5 resistance assay; aDI-2GPI: anti-domain-I 2-glycoprotein-I antibody; APC: 
activated protein C; SD: standard deviation 
 
*n=16 for aPL-positive patients 
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Follow-up data 
We analyzed follow-up data for the 17 aPL-positive subjects who completed 12 weeks 
of study follow up. As shown in Table 3, values for AnxA5-RA, aDI-β2GPI, APC 
resistance, and D-dimer did not change significantly from baseline to 12 weeks in 
aPL-positive subjects taking HCQ. There was also no significant change in LAC 
status, aCL or aβ2GPI titers (data not shown). 
 
Table 3: Comparison of Baseline and Week 12 Values for Non-criteria aPL Tests in 
aPL-positive Subjects (n=17) 
 Baseline 12 weeks p Reference Range 
AnxA5-RA (%) 
(Mean + SD) 
136.6.1  16.0 143.96 ± 25.6 0.2435 
Negative 153 
Borderline 140-152.9 
Positive <140 
aDI-β2GPI (mg/L) 
(Mean + SD) 
4.45  4.80 4.01  4.40 0.9265 
Negative 1.66 
Borderline 1.66-2.29 
Positive >2.29 
APC resistance 
ratio* 
2.69  0.63 2.52  0.92 0.7002 Abnormal <2.0 
D-dimer (µg/mL) 
(Mean + SD) 
1.73  0.72 1.58  0.72 0.1743 Normal 
0.8-2.3 
AnxA5-RA: Annexin-A5 resistance assay; aDI-2GPI: anti-domain-I 2-glycoprotein-I antibody; 
APC: activated protein C; SD: standard deviation 
 
* n = 14 
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We further analyzed the subpopulation of APS subjects to assess for a change in these 
test results from baseline to week 12.  Twelve of the 13 subjects with APS completed 
12 weeks of study follow up. As shown in Table 4, values for AnxA5-RA, aDI- 
β2GPI, APC resistance, and D-dimer did not change from baseline to 12 weeks in 
subjects with APS taking HCQ. 
 
Table 4: Comparison of Baseline and Week 12 Values for Non-criteria aPL Tests in 
Subjects with APS (n=12) 
 Baseline  12 weeks p Reference Range 
 
AnxA5-RA (%) 
(Mean + SD) 
133.8  17.0 145.0 ± 29.0 0.151 
Negative 153 
Borderline 140-152.9 
Positive <140 
aDI-β2GPI (mg/L) 
(Mean + SD) 
5.0  4.8 4.2  4.1 0.791 
Negative 1.66 
Borderline 1.66-2.29 
Positive >2.29 
APC resistance 
ratio* 
 
2.4  0.6 
 
2.5  0.6 
 
0.156 
 
Abnormal <2.0 
D-dimer (µg/mL) 
(Mean + SD) 
1.80  0.83 1.74  0.77 0.5186 Normal 
0.8-2.3 
AnxA5-RA: Annexin-A5 resistance assay; aDI-2GPI: anti-domain-I 2-glycoprotein-I antibody; 
APC: activated protein C; SD: standard deviation  
 
* n = 9  
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Discussion 
aPL-mediated interference with the AnxA5 anticoagulant layer over cells plays a role 
in the pathogenesis of APS,12-14 and patients with aPL have reduced AnxA5 
anticoagulant activity. HCQ reverses the effects of aPL and restores AnxA5 
expression on cell surfaces.15,16  
 
In this study, subjects with aPL have reduced AnxA5 anticoagulant activity and 
elevated titers of aDI-2GPI.  Others have remarked on the particular importance of 
aDI-2GPI in the pathogenesis of APS as domain I is a major antigenic target for 
thrombogenic aPL.17  Our findings support the use of the AnxA5-RA and aDI-2GPI 
tests to detect potentially pathogenic aPL.  
 
Our study confirms the observations of previous studies by showing that aPL-positive 
subjects have abnormal baseline AnxA5-RA measurements compared to aPL-negative 
control subjects (SLE-only individuals in this study). We did not demonstrate a 
significant difference in the baseline AnxA5-RA between asymptomatic aPL-positive 
individuals and those with thrombotic APS, suggesting that this assay does not 
distinguish those with historical thrombosis from those without; follow-up of those 
asymptomatic aPL-positive individuals with abnormal AnxA5-RA are warranted to 
determine if the assay is of those individuals who will develop future thrombosis. 
 
We did not demonstrate a change in the AnxA5-RA over a 12 week time period in 
subjects taking HCQ.  There are several possible explanations. One is that 12 weeks is 
not a sufficient period of time to detect a change in the assay. Lack of medication 
adherence is another possibility. Although we considered that the dosing of HCQ may 
not have resulted in therapeutic levels of the drug, we did not measure HCQ levels in 
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this study. Finally, this pilot study was not powered to detect a change within groups 
over time, but was intended to be hypothesis-generating for future studies. Though not 
definitive, our findings suggest that HCQ may not act through an AnxA5 resistance 
mechanism.  
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